Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH ... - Morningstar
FDA grants 7-year market exclusivity to YORVIPATH for treating hypoparathyroidism in adults.
Reference News
The FDA has granted Ascendis Orphan Drug exclusivity in the United States - MedWatch
Ascendis Pharma granted US Orphan Drug exclusivity for Yorvipath, preventing other companies from marketing similar drugs for adult hypoparathyroidism treatment.
Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH ... - Morningstar
FDA grants 7-year market exclusivity to YORVIPATH for treating hypoparathyroidism in adults.